Developing Story: How PCDI Is Changing the Way We Think About Dosing
What if the highest dose isn't the right dose? Victoria talks with the Patient-Centered Dosing Initiative team about two groundbreaking surveys revealing that lower doses of cancer drugs can be just as effective, while dramatically improving quality of life. Learn why patients are having dose reduction conversations with their doctors, what real-world data shows about side effects, and how you can advocate for personalized treatment.
Developing Story: From CLEOPATRA to Life on Enhertu – HER2+ MBC with Dr. Erika Hamilton & Dr. Sarah Premji
wenty-five years ago, HER2-positive breast cancer meant a two-year death sentence. Today, patients are living 12+ years on first-line treatment—and some are being cured.
In this deep dive, host Victoria Goldberg (living with metastatic HER2+ cancer for 12 years) and leading oncologists Dr. Erika Hamilton and Dr. Sarah Premji unpack the drugs, trials, and real-world strategies transforming one of cancer's most feared diagnoses into its greatest success story.
From CLEOPATRA's game-changing 16-month survival boost to antibody-drug conjugates that deliver chemotherapy straight to cancer cells, learn how precision medicine is rewriting the rules—and what patients need to know about side effects, sequencing, and hope.
Developing Story: Triple Negative MBC - Hard Truths, Real Hope with Dr Sarah Premji
Triple negative metastatic breast cancer has long been considered the hardest subtype to treat. That is changing and faster than most patients realize. Dr. Sarah Premji joins Victoria Goldberg to break down two landmark FDA approvals, the science behind antibody-drug conjugates, and what's coming next in the pipeline